Several studies have shown that some kinases founded in breast cancer, melanoma and hematopoietic malignancies are able to regulate the function of CDK6 and CDK4, which makes CDK6 an attractive target for therapeutic disruption.6 This evidence concerns the gene CDK4 and breast carcinoma.